Abstract
Gastro-esophageal reflux disease (GERD) has increased in Japan, as in other countries. This is probably due to increased acid secretion among Japanese due to Westernized foods and lifestyle as well as decreased prevalence of Helicobacter pylori infection. Proton pump inhibitor (PPI) is mainly used for treatment of this condition. PPI has recently been approved for treatment of nonerosive reflux disease (NERD) in Japan. NERD is known to have different characteristics to GERD, and effectiveness of PPI in NERD patients is lower than that in reflux esophagitis patients. Regarding therapeutic benefit of treatment, a recent study showed that PPI improved quality of life (QOL) of GERD patients also in Japan. For diagnosis of reflux esophagitis in Japan, we use a unique classification, a modified Los Angeles (LA) classification, which includes minimal change (grade M esophagitis) as one distinct criteria. However, recent studies from Japan showed poor interobserver agreement in diagnosis of grade M, although excess acid reflux in minimal change was shown in another study. Our definition of Barrett’s esophagus is also different from that in the West. Nationwide consensus on diagnosis of reflux esophagitis and Barrett’s esophagus should be achieved in Japan, preferably consistent with world standard.
Similar content being viewed by others
References
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20.
Miwa H. New conceptual framework of GERD—especially regarding pathophysiology of NERD and Barrett’s esophagus (in Japanese with English abstract). Nippon Shokakibyo Gakkai Zasshi. 2006;103(8):901–10.
El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43(3):327–33.
Mishima I, Adachi K, Arima N, Amano K, Takashima T, Moritani M, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40(9):1005–9.
Manabe N, Haruma K, Mihara M, Ohshima T, Miwa H, Iwakiri R, et al. The increasing incidence of reflux esophagitis during the past 20 years in Japan. Gastroenterology 1999;116(4):A244.
Ohara S, Kouzu T, Kawano T, Kusano M. Nationwide epidemiological survey regarding heartburn and reflux esophagitis in Japanese. Nippon Shokakibyo Gakkai Zasshi. 2005;102(8):1010–24.
Okamoto K, Iwakiri R, Mori M, Hara M, Oda K, Danjo A, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8,031 adult subjects. Dig Dis Sci. 2003;48(12):2237–41.
Shimizu T, Matsui T, Furukawa K, Oshige K, Mitsuyasu T, Kiyomizu A, et al. A prospective study of the prevalence of gastroesophageal reflux disease and confounding factors. J Gastroenterol. 2005;40(9):866–72.
Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41(4):452–8.
Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102(3):760–6.
Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999;94(8):2094–9.
Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326(7392):737.
Miwa H, Hojo M, Ohkusa T, Sato N. Gastroesophageal reflux diseases and Helicobacter pylori infection. Karnataka Med J. 2003;73(2):8–12.
Matsuhisa T, Matsukura N, Yamada N. Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations: age-, gender-, and endoscopic diagnosis-matched study. J Gastroenterol. 2004;39(4):324–8.
Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55(11):1545–52.
Yoshiike N, Matsumura Y, Yamaguchi M, Seino F, Kawano M, Inoue K, et al. Trends of average intake of macronutrients in 47 prefectures of Japan from 1975 to 1994—possible factors that may bias the trend data. J Epidemiol. 1998;8:160–7.
Yoshiike N, Seino F, Tajima S, Arai Y, Kawano M, Furuhata T, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: the National Nutrition Survey 1976–95. Obes Rev. 2002;3(3):183–90.
Yamaguchi T, Sugimoto T, Yamada H, Kanzawa M, Yano S, Yamauchi M, et al. The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int. 2002;13(4):331–6.
Takemitsu Y, Harada Y, Iwahara T, Miyamoto M, Miyatake Y. Lumbar degenerative kyphosis. Clinical, radiological and epidemiological studies. Spine. 1988;13(11):1317–26.
Fujimoto K, Iwakiri R, Okamoto K, Oda K, Tanaka A, Tsunada S, et al. Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. J Gastroenterol. 2003;38(Suppl 15):3–6.
El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2002;37(8):899–904.
Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32(10):974–9.
Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol. 1998;10(2):119–24.
Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26(1):69–77.
Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol. 2005;100(4):754–8.
Prasad M, Rentz AM, Revicki DA. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review. Pharmacoeconomics. 2003;21(11):769–90.
Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:S46–S53.
Hongo M, Kinoshita Y, Miwa H, Ashida K. The demographic characteristics and health-related quality of life in a large cohort of reflux esophagitis patients in Japan with reference to the effect of lansoprazole: the REQUEST study. J Gastroenterol (in press).
Adachi K, Hashimoto T, Komazawa Y, Adachi K, Hashimoto T, Komazawa Y, et al. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD—crossover comparative study with famotidine and low-dose lansoprazole. Dig Liver Dis. 2005;37(7):485–90.
Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006;41(6):554–61.
Ashida K, Hongo M. Pharmacodynamic efficacy of lansoprazole(AG–1749)15 mg and 30 mg in controlling intraesophageal pH in Japanese patients with non-erosive reflux disease as assessed by 24-hour intraesophageal pH monitoring—a randomized, multi-center, double blind trial (in Japanese with English abstract). Jpn Pharmacol Ther. 2008;36(7):641–54.
Hongo M, Hoshihara Y. Efficacy and safety of lansoprazole(AG–1749)15 mg and 30 mg in Japanese patients with non-erosive reflux disease(NERD)—a phase III multicenter, double-blind, placebo-controlled trial (in Japanese with English abstract). Jpn Pharmacol Ther. 2008;36(7):655–71.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2(8):656–64.
Galmiche JP, Stephenson K. Treatment of gastroesophageal reflux disease in adults: an individualized approach. Dig Dis. 2004;22(2):148–60.
Ang D, Sifrim D, Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol. 2008;5(7):383–92.
Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. Strategy for treatment of nonerosive reflux disease in Asia. World J Gastroenterol. 2008;14(20):3123–8.
Hoshihara Y, Hashimoto M. Endoscopic classification of reflux esophagitis (in Japanese with English abstract). Nippon Rinsho. 2000;58:1808–12.
Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41:95–9.
Amano Y, Ishimura N, Furuta K, Amano Y, Ishimura N, Furuta K, et al. Interobserver agreement on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy. 2006;38(10):1032–5.
Miwa H, Yokoyama T, Hori K, Sakagami T, Oshima T, Tomita T, et al. Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists. Dis Esophagus. 2008;21(4):355–6.
Joh T, Miwa H, Higuchi K, Shimatani T, Manabe N, Adachi K, et al. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol. 2007;42(6):444–9.
Hoshihara Y, Kogure T, Yamamoto T, Hashimoto M, Hoteya O. Endoscopic diagnosis of Barrett’s esophagus (in Japanese with English abstract). Nippon Rinsho. 2005;63(8):1394–8.
Ogiya K, Kawano T, Ito E, Nakajima Y, Kawada K, Nishikage T, et al. Lower esophageal palisade vessels and the definition of Barrett’s esophagus. Dis Esophagus. 2008. doi:10.1111/j.1442-2050.2008.00825.
Kawano T, Kouzu T, Ohara S, Kusano M. The prevalence of Barrett’s mucosa in the Japanese (in Japanese with English abstract). Gastroenterol Endosc. 2005;47(4):951–61.
Amano Y, Ishimura N, Furuta K, Takahashi Y, Chinuki D, Mishima Y, et al. Which landmark results in a more consistent diagnosis of Barrett’s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64(2):206–11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miwa, H., Oshima, T., Tomita, T. et al. Gastro-esophageal reflux disease: the recent trend in Japan. Clin J Gastroenterol 1, 133–138 (2008). https://doi.org/10.1007/s12328-008-0039-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-008-0039-7